Home > Neurology > EAN 2020 > Multiple Sclerosis > Two trials comparing relapsing MS treatments

Two trials comparing relapsing MS treatments

Ofatumumab markedly reduced disability progression independent of relapses versus teriflunomide [1]. In another head-to-head trial, ponesimod was superior to teriflunomide with regard to annualised relapse rate (ARR), fatigue symptoms, MRI activity, brain atrophy, and no evidence of disease activity (NEDA) in the OPTIMUM study [2,3].

In a pooled analysis of the phase 3 ASCLEPIOS I/II trials in relapsing multiple sclerosis (RMS) patients, the effect of ofatumumab versus teriflunomide on confirmed disability progression independent of relapse activity (PIRA) was assessed. The risk of confirmed disability progression at 3/6 months (3mCDP/6mCDP) was evaluated in 3 subsets of patients:
A: without confirmed relapses during the study;
B: without confirmed relapses duri...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on